Continuous subcutaneous infusion of growth hormone (CSIGH) in GH deficiency

Clicks: 312
ID: 116816
1970
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #30 of 80 articles by views in Pediatric research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
In contrast to the sustained acceleration of growth observed in pituitary hypersecretion in GH, full catch-up growth is rarely attained in GH deficiency with conventional GH Rx (0.1 U/kg IM 3x/wk). Since circulating GH levels are very low for all but 24-30 hr per wk during conventional Rx, we examined the feasibility and metabolic effects of CSIGH using a small infusion pump. Somatomedin-C (SM-C), oral glucose tolerance (GT) and free fatty acids were determined in 7 untreated deficient children before and after 85 hrs of CSIGH (2.1 μU/kg/hr ≃ 0.3 U/kg/wk). CSIGH maintained serum GH at 3-9 ng/ml and produced a modest increase in fasting (0 min) G and I. Glucose tolerance was impaired despite 2-fold higher I levels (*p
Reference Key
gertner1970pediatriccontinuous Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors J Gertner;S Page;W Tamborlane;J Gertner;S Page;W Tamborlane;
Journal Pediatric research
Year 1970
DOI
doi:10.1203/00006450-198112000-00091
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.